The antibody targets the acetylated lysine 8 (K8) residue on histone H4, encoded by the HIST1H4A gene. Key features include:
Validated for multiple techniques in epigenetics and cell biology research:
Detects a single band at ~11 kDa in HeLa cell lysates, corresponding to acetylated histone H4 .
Controls: Recombinant histone H4 (positive), unmodified histone H2A/H2B (negative) .
Nuclear localization: Staining in HeLa cells confirms acetylation in euchromatin regions .
Blocking peptide validation: Loss of signal when incubated with acetylated K8 peptide .
Tissue-specific staining: Detected in human glioma and placental samples, highlighting acetylation patterns in pathologic and developmental contexts .
The antibody demonstrates stringent specificity for K8 acetylation, as evidenced by:
Epigenetic studies: Used to map K8ac-enriched regions in chromatin, linking acetylation to transcriptional activation .
Cancer research: Detects acetylation patterns in glioma and breast carcinoma tissues, aiding in understanding tumor biology .
Drug development: Validates inhibitors of histone deacetylases (HDACs) that modulate K8 acetylation .
| Vendor | Catalog # | Key Features |
|---|---|---|
| Biorbyt | orb517120 | Validated for ChIP, ELISA, IF, IHC, WB |
| Abbexa | CAC15455 | Reactivity: Human, Mouse, Rat |
| Biomatik | CAC15455 | Includes blocking peptide compatibility |